LPL and cancer: LPL, CD36, FATP1 (SLC27A1), and FATP2 (SLC27A2), implicated in increased FA uptake into melanoma cells (Alicea et al., 2020; Henderson et al., 2019; Pascual et al., 2017; Zhang et al., 2018), are unaffected by point mutation in cancer and display gene amplification in 2%–8% of cases (Figure S1A).